COSCIENS Biopharma Inc. ("COSCIENS" or the "Company"), a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, ...

The company also announced the initiation of a Phase 2a clinical study for its avenanthramide-based product, following a successful Phase 1 trial. In leadership developments, COSCIENS appointed ...

TORONTO, ONTARIO, April 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company ...

results from our avenanthramide product and other products under development may not be successful or may not support advancing the product; the failure of the DETECT-trial to achieve its primary ...

25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels GlobeNewswire, Inc.

Ongoing streamlined efficiencies and cost cutting measures taken to refine operations and development pathway forward; Company ended the quarter with US$16.4 million in cash ...

Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization ...

Additionally, COSCIENS has begun a Phase 2a clinical efficacy study for its avenanthramide-based product, following a successful Phase 1 trial. This study, conducted at the Montreal Heart Institute, ...

Additionally, COSCIENS has begun a Phase 2a clinical efficacy study for its avenanthramide-based product, following a successful Phase 1 trial. This study, conducted at the Montreal Heart ...

results from our avenanthramide product and other products under development may not be successful or may not support advancing the product; the failure of the DETECT-trial to achieve its primary ...